{
    "id": 17224,
    "fullName": "FGFR2 - AHCYL1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2-AHCYL1 results from the fusion of FGFR2 and AHCYL1, resulting in the ability to activate MAPK signaling and induce transformation of cells in culture and in animal models (PMID: 24122810).",
            "references": [
                {
                    "id": 4202,
                    "pubMedId": 24122810,
                    "title": "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24122810"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "FGFR2 - AHCYL1",
    "createDate": "01/25/2016",
    "updateDate": "07/17/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 10768,
                "geneSymbol": "AHCYL1",
                "terms": [
                    "AHCYL1",
                    "DCAL",
                    "IRBIT",
                    "PPP1R78",
                    "PRO0233",
                    "XPVKONA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 4214,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810).",
            "molecularProfile": {
                "id": 17510,
                "profileName": "FGFR2 - AHCYL1"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4202,
                    "pubMedId": 24122810,
                    "title": "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24122810"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4213,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BGJ398 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810).",
            "molecularProfile": {
                "id": 17510,
                "profileName": "FGFR2 - AHCYL1"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4202,
                    "pubMedId": 24122810,
                    "title": "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24122810"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20595,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, a patient with intrahepatic cholangiocarcinoma harboring FGFR2-AHCYL1 demonstrated stable disease when treated with Derazantinib (ARQ 087) (PMID: 30420614; NCT01752920).",
            "molecularProfile": {
                "id": 17510,
                "profileName": "FGFR2 - AHCYL1"
            },
            "therapy": {
                "id": 2900,
                "therapyName": "Derazantinib",
                "synonyms": null
            },
            "indication": {
                "id": 4928,
                "name": "intrahepatic cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17949,
                    "pubMedId": 30420614,
                    "title": "Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30420614"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17510,
            "profileName": "FGFR2 - AHCYL1",
            "profileTreatmentApproaches": [
                {
                    "id": 7595,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR2 - AHCYL1"
                },
                {
                    "id": 7596,
                    "name": "FGFR2 Inhibitor",
                    "profileName": "FGFR2 - AHCYL1"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}